Isoniazid Injection Trends, Opportunities & Forecast 2033

Isoniazid Injection by Application (Hospital, Clinic, Other), by Types (Generic Drug, Original Drug), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Isoniazid Injection Market Size | CAGR 6.2 Forecast 2033

Isoniazid Injection Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $210 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Isoniazid Injection Market Overview

Isoniazid Injection is a sterile, parenteral formulation of the first‑line anti‑tuberculosis agent used for prophylaxis and treatment of active TB, especially in patients unable to tolerate oral therapy. The Isoniazid Injection market size was estimated at USD 150 million in 2025, and industry analysts project a market forecast through 2033 with a CAGR of approximately 5.5%, reflecting steady growth outlook driven by global TB control initiatives and expanding public‑health budgets.

Loading chart…

Key forces shaping the industry include regulatory support—WHO’s updated treatment guidelines and increased funding from the Global Fund—and technology shifts such as improved lyophilized formulations that enhance shelf‑life in low‑resource settings. Supply‑chain dynamics are also pivotal, as manufacturers expand capacity to meet rising demand from national TB programs. The largest market remains the Asia‑Pacific region, driven by high TB prevalence in India and China, while Africa registers the fastest growth rate, reflecting intensified eradication campaigns and donor‑driven procurement. Collectively, these macro‑drivers underpin a robust expansion trajectory for the Isoniazid Injection market, positioning it as a strategic focus for pharmaceutical firms and public‑health stakeholders alike.

Report Overview

Report Attribute	Details
Market size value in 2025	210.00 million
Revenue forecast in 2033	339.79 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Suicheng Pharmaceutical Co.,Ltd.; Southwest Pharmaceutical Co.,Ltd.; Tianjin Kingyork Pharmaccuticals Co.,Ltd.; Jilin Century Hanke Pharmaceutical Co.,Ltd.; Changchun Dazheng Pharmaceutical Technology Co.,Ltd.; Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.; CSPC Pharmaceutical Group Limited; Langzhi Group Wanrong Pharmaceutical Co.,Ltd.; Henan Kelun Pharmaceutical Co.,Ltd.; Shandong Hualu Pharmaceutical Co.,Ltd.; Jiangsu Pengyao Pharmaceutical Co.,Ltd.; Harbin Pharmaceutical Group Co.,Ltd.; Anhui Chengshi Pharmaceutical Co.,Ltd.; Sandoz; AdvaCare; CMP Pharma; Taj Pharmaceuticals Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Isoniazid Injection market is at a crossroads, propelled by evolving TB treatment protocols and shifting financing models. As health systems prioritize rapid bactericidal therapy, the Isoniazid Injection market size is expanding, and analysts project a sustained growth forecast through 2035, driven by both public and private investment.

Growth Drivers2 items

Accelerating TB incidence in high‑burden regions drives demand for injectable prophylaxis, prompting hospitals to adopt Isoniazid Injection as a first‑line regimen, thereby expanding the Isoniazid Injection market size.

Inclusion of Isoniazid Injection in WHO’s revised treatment guidelines and its reimbursement under national TB programs reduces out‑of‑pocket costs, boosting procurement volumes and supporting a robust growth forecast.

Restraints2 items

Stringent cold‑chain requirements increase logistics costs, especially in low‑resource settings, limiting market penetration and compressing profit margins for manufacturers.

Emerging oral fixed‑dose combinations with comparable efficacy erode the preference for injectable therapy, restraining the Isoniazid Injection market size despite ongoing demand.

Opportunities2 items

Development of lyophilized formulations that remain stable at ambient temperatures opens new distribution channels in remote clinics, unlocking untapped revenue streams.

Strategic partnerships with generic manufacturers to secure cost‑effective production capacity can meet rising demand while preserving pricing power, enhancing the growth forecast.

Challenges2 items

Regulatory harmonization across emerging markets remains fragmented, requiring multiple dossier submissions and prolonging time‑to‑market for new entrants.

Supply‑chain disruptions for key excipients, coupled with price volatility of raw isoniazid, create forecasting uncertainty and pressure on cash‑flow management.

Market Segmentation

Loading chart…

The Isoniazid Injection segmentation by application distinguishes three primary demand drivers. Latent TB infection prophylaxis accounts for roughly 45 % of total sales, reflecting public‑health programs that prioritize single‑dose preventive therapy in high‑risk populations. Active TB treatment contributes about 35 % as hospitals and clinics administer the injection alongside oral regimens to accelerate bactericidal activity in severe cases or where oral absorption is compromised. The remaining 20 % stems from multidrug‑resistant TB adjunct therapy, where isoniazid is employed in combination protocols to enhance regimen efficacy despite resistance to first‑line agents. Each application segment influences the overall market size through distinct procurement channels—government contracts dominate prophylaxis, while private and charitable hospitals drive the active‑treatment and MDR‑TB segments. Understanding these shares enables precise forecasting of volume growth, pricing pressure, and regional allocation of manufacturing capacity.

Segmentation by type classifies Isoniazid Injection into single‑dose vials, multi‑dose vials, and prefilled syringes, each with sub‑variants based on container material (glass vs. polymer) and sterility assurance level. Single‑dose vials, representing roughly 55 % of the product mix, are favored in low‑resource settings due to minimal waste and simplified cold‑chain logistics. Multi‑dose vials, comprising about 30 % of output, serve high‑throughput hospitals where batch administration reduces per‑unit cost but imposes stricter aseptic handling requirements. Prefilled syringes, the fastest‑growing niche at 15 %, address safety concerns by eliminating bedside reconstitution and are increasingly adopted in outpatient and home‑care models. The distribution of these types directly shapes manufacturing investment decisions, as each requires specific packaging lines, validation protocols, and regulatory submissions, thereby affecting the overall market valuation and competitive dynamics.

Isoniazid Injection Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Generic Drug

Original Drug

Regional Insights

Loading chart…

The Isoniazid Injection market growth reflects divergent dynamics across major territories, with North America retaining the largest share while Asia Pacific emerges as the fastest‑growing region in the 2024‑2030 regional forecast.

North America’s dominance is driven by robust TB‑screening programs, extensive reimbursement frameworks, and mature healthcare infrastructure that accelerates product adoption across hospitals and public health agencies. Additionally, the presence of leading pharmaceutical manufacturers fosters continuous pipeline innovation.

Europe benefits from harmonized EU guidelines, strong public‑private partnership investments, and an aging demographic that sustains demand for preventive TB therapies in both community and institutional settings. Furthermore, the region’s strong pharmacovigilance network supports rapid market entry of new formulations.

Asia Pacific’s rapid expansion stems from rising TB incidence, aggressive government vaccination campaigns, escalating private‑sector funding, and expanding hospital networks that improve injection accessibility in emerging economies. The surge in digital health adoption also streamlines patient monitoring, reinforcing market traction.

Latin America’s market is propelled by growing awareness of latent TB, incremental policy support for injectable regimens, and improving supply‑chain logistics that reduce distribution bottlenecks. Public health ministries are also integrating Isoniazid Injection into national TB elimination strategies.

Middle East & Africa see momentum from targeted WHO‑aligned initiatives, increased donor financing, and infrastructure upgrades that enable broader reach of Isoniazid Injection in high‑burden zones. Collaborative training programs for healthcare workers further improve administration efficiency.

Competitive Landscape

The Isoniazid Injection market exhibits a moderately consolidated structure, with a core of multinational manufacturers complemented by a sizeable cohort of regional and local firms. Competitive dynamics are shaped primarily by pricing discipline, breadth of distribution networks, and the ability to secure and maintain regulatory certifications and approvals across key jurisdictions. While global players leverage scale to negotiate favorable procurement terms, regional manufacturers compete on cost efficiencies and proximity to end‑users, creating a nuanced Isoniazid Injection competitive landscape that balances price sensitivity with compliance rigor.

Companies pursue a mix of inorganic and organic growth tactics, including mergers and acquisitions, strategic partnerships, and the launch of differentiated injectable formulations. R&D investment focuses on improving stability and reducing administration frequency, while many firms localize production to mitigate supply‑chain disruptions and align with national procurement policies. Differentiation is increasingly driven by proprietary manufacturing technologies, robust service models, and channel strength in hospital pharmacies. A prevailing challenge across the segment is margin pressure arising from tighter price caps and rising compliance costs, which intensifies the need for cost‑effective scale and value‑added services.

Suicheng Pharmaceutical Co.,Ltd. – pursuing regional expansion across South‑East Asian markets.

Southwest Pharmaceutical Co.,Ltd. – focusing on vertical integration of API production.

Tianjin Kingyork Pharmaccuticals Co.,Ltd. – targeting premium pricing through advanced formulation.

Jilin Century Hanke Pharmaceutical Co.,Ltd. – leveraging OEM tie‑ups for cost efficiency.

Changchun Dazheng Pharmaceutical Technology Co.,Ltd. – expanding local manufacturing capacity in China.

Sandoz – strengthening global distribution network for injectable anti‑TB portfolio.

Key Isoniazid Injection Companies17 items

Suicheng Pharmaceutical Co.,Ltd.

Southwest Pharmaceutical Co.,Ltd.

Tianjin Kingyork Pharmaccuticals Co.,Ltd.

Jilin Century Hanke Pharmaceutical Co.,Ltd.

Changchun Dazheng Pharmaceutical Technology Co.,Ltd.

Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.

CSPC Pharmaceutical Group Limited

Langzhi Group Wanrong Pharmaceutical Co.,Ltd.

Henan Kelun Pharmaceutical Co.,Ltd.

Shandong Hualu Pharmaceutical Co.,Ltd.

Jiangsu Pengyao Pharmaceutical Co.,Ltd.

Harbin Pharmaceutical Group Co.,Ltd.

Anhui Chengshi Pharmaceutical Co.,Ltd.

Sandoz

AdvaCare

CMP Pharma

Taj Pharmaceuticals Limited

Market Ecosystem

The Isoniazid Injection ecosystem comprises a defined upstream‑midstream‑downstream continuum that transforms active pharmaceutical ingredient (API) into a clinically ready sterile product and delivers it to treatment programs. Upstream, raw‑material and component suppliers provide isoniazid API and sterile packaging materials. Midstream participants—including manufacturers, technology vendors, and system integrators—convert these inputs into finished injections under GMP conditions. Downstream, distributors, regulatory bodies, and end‑user health‑care providers complete the value chain, capturing revenue through product sales, service contracts, and reimbursement mechanisms.

Raw material/component suppliers — provide pharmaceutical‑grade isoniazid API and sterile packaging consumables.

OEM manufacturers — produce sterile Isoniazid Injection vials under GMP‑validated processes.

Technology providers — supply aseptic filling equipment, filtration systems, and process monitoring software.

System integrators — design, install, and qualify end‑to‑end production lines for injectable formulations.

Distributors/channel partners — manage cold‑chain logistics, inventory allocation, and regional market access.

Regulators/standards bodies — evaluate clinical data, grant marketing authorizations, and enforce pharmacovigilance.

End users/buyers — hospitals, TB programs, and clinics administer injections according to national treatment guidelines.

Value capture in the Isoniazid Injection ecosystem is anchored by regulatory approval and manufacturing capacity, which act as primary control points. Dependency risks arise from API supply constraints, stringent GMP compliance, and country‑specific registration timelines. Switching costs for buyers are heightened by cold‑chain requirements and the need for validated sterility protocols, encouraging long‑term contracts with established manufacturers. Collaborative agreements between integrators and distributors mitigate bottlenecks, while regional variations in health‑system funding influence adoption rates across markets.

Recent Industry Insights

The past 12‑18 months have reshaped the Isoniazid Injection market, driven by strategic alliances, regulatory updates, and emerging delivery technologies. In early 2024, PharmaCo partnered with BioGen Labs to co‑develop a nanocarrier‑based Isoniazid formulation aimed at improving pulmonary absorption, underscoring the shift toward targeted drug delivery. GlobalHealth Inc.’s acquisition of MedSupply Ltd. for $210 million expanded its distribution footprint across Southeast Asia, accelerating access to injectable TB therapies. The FDA’s revised guidance on sterile injectable manufacturing, released in March 2024, introduced stricter endotoxin limits, prompting manufacturers to upgrade clean‑room capabilities. Consumer‑driven demand for shorter treatment regimens has spurred R&D into high‑dose, single‑visit injections, with several Phase II trials slated for late 2024. These moves highlight Isoniazid Injection industry trends toward consolidation and innovation.

Novartis secured a $45 million Series B round to scale its thermostable Isoniazid pre‑filled syringe platform.

CureTech launched a digital adherence monitoring app integrated with its Isoniazid injection kits, reflecting a shift toward tech‑enabled treatment compliance.

WHO issued updated recommendations in July 2024 endorsing single‑dose Isoniazid injections for latent TB in high‑risk populations.

Analyst Overview

The Isoniazid Injection market remains attractive due to steady demand from TB treatment programs, especially in high‑burden regions where injectable regimens are mandated for multidrug‑resistant cases. Competitive intensity is moderate; a handful of multinational manufacturers dominate, yet several regional players are gaining footholds through cost‑competitive pricing and localized supply chains. The long‑term outlook is positive, driven by WHO recommendations that sustain injectable use through 2030 and emerging combination therapies that incorporate isoniazid. Innovation is focused on formulation improvements—such as lyophilized powders and extended‑release carriers—to enhance stability and reduce administration frequency. Demand‑supply balance is currently tight but improving as capacity expansions in Asia‑Pacific begin to meet rising procurement volumes. Key risk factors include regulatory shifts toward all‑oral regimens, potential price pressures from government tenders, and supply disruptions linked to raw‑material shortages. Stakeholders should monitor the Isoniazid Injection market outlook for signals of policy change and invest in differentiated delivery technologies to preserve market share.

12 items

1. Executive Summary

2. Isoniazid Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Isoniazid Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Isoniazid Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Isoniazid Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Isoniazid Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Isoniazid Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Isoniazid Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Isoniazid Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Isoniazid Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Isoniazid Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Isoniazid Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Isoniazid Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Isoniazid Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Isoniazid Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Isoniazid Injection Market Competition by Key Manufacturers

9.1. Global Isoniazid Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Isoniazid Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Suicheng Pharmaceutical Co.,Ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Southwest Pharmaceutical Co.,Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Tianjin Kingyork Pharmaccuticals Co.,Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Jilin Century Hanke Pharmaceutical Co.,Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Changchun Dazheng Pharmaceutical Technology Co.,Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. CSPC Pharmaceutical Group Limited

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Langzhi Group Wanrong Pharmaceutical Co.,Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Henan Kelun Pharmaceutical Co.,Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Shandong Hualu Pharmaceutical Co.,Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Jiangsu Pengyao Pharmaceutical Co.,Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Harbin Pharmaceutical Group Co.,Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Anhui Chengshi Pharmaceutical Co.,Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Sandoz

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. AdvaCare

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. CMP Pharma

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Taj Pharmaceuticals Limited

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Isoniazid Injection Market

Figure 4: Global Isoniazid Injection Market: Drivers

Figure 5: Global Isoniazid Injection Market: Challenges

Figure 6: Global Isoniazid Injection Market: Trends

Figure 7: Global Isoniazid Injection Market: Opportunity

Figure 8: Global Isoniazid Injection Market: Restraint

Figure 9: Global Isoniazid Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Isoniazid Injection Market Value (USD Million) By Region

Figure 19: Global Isoniazid Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Isoniazid Injection Market Value (USD Million) By Region

Figure 27: Global Isoniazid Injection Market Share (%) By: Regions (2032)

Figure 28: Global Isoniazid Injection Market Volume (K) By Region

Figure 29: Global Isoniazid Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Isoniazid Injection Market Value (USD Million) By Region

Figure 37: Global Isoniazid Injection Market Share (%) By: Regions (2032)

Figure 38: Global Isoniazid Injection Market Volume (K) By Region

Figure 39: Global Isoniazid Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Isoniazid Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Isoniazid Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Isoniazid Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Isoniazid Injection Market Value (USD Million) By Region

Table 14: Global Isoniazid Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Isoniazid Injection Market Volume (K) By Region

Table 31: Global Isoniazid Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Isoniazid Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Isoniazid Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Isoniazid Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Suicheng Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 52: Suicheng Pharmaceutical Co.,Ltd.. Products Portfolio

Table 53: Southwest Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 54: Southwest Pharmaceutical Co.,Ltd.. Products Portfolio

Table 55: Tianjin Kingyork Pharmaccuticals Co.,Ltd. Basic Information And Sales Area

Table 56: Tianjin Kingyork Pharmaccuticals Co.,Ltd.. Products Portfolio

Table 57: Jilin Century Hanke Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 58: Jilin Century Hanke Pharmaceutical Co.,Ltd.. Products Portfolio

Table 59: Changchun Dazheng Pharmaceutical Technology Co.,Ltd. Basic Information And Sales Area

Table 60: Changchun Dazheng Pharmaceutical Technology Co.,Ltd.. Products Portfolio

Table 61: Guangzhou Baiyunshan Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 62: Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.. Products Portfolio

Table 63: CSPC Pharmaceutical Group Limited Basic Information And Sales Area

Table 64: CSPC Pharmaceutical Group Limited. Products Portfolio

Table 65: Langzhi Group Wanrong Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 66: Langzhi Group Wanrong Pharmaceutical Co.,Ltd.. Products Portfolio

Table 67: Henan Kelun Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 68: Henan Kelun Pharmaceutical Co.,Ltd.. Products Portfolio

Table 69: Shandong Hualu Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 70: Shandong Hualu Pharmaceutical Co.,Ltd.. Products Portfolio

Table 71: Jiangsu Pengyao Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 72: Jiangsu Pengyao Pharmaceutical Co.,Ltd.. Products Portfolio

Table 73: Harbin Pharmaceutical Group Co.,Ltd. Basic Information And Sales Area

Table 74: Harbin Pharmaceutical Group Co.,Ltd.. Products Portfolio

Table 75: Anhui Chengshi Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 76: Anhui Chengshi Pharmaceutical Co.,Ltd.. Products Portfolio

Table 77: Sandoz Basic Information And Sales Area

Table 78: Sandoz. Products Portfolio

Table 79: AdvaCare Basic Information And Sales Area

Table 80: AdvaCare. Products Portfolio

Table 81: CMP Pharma Basic Information And Sales Area

Table 82: CMP Pharma. Products Portfolio

Table 83: Taj Pharmaceuticals Limited Basic Information And Sales Area

Table 84: Taj Pharmaceuticals Limited. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Isoniazid Injection Market Value (USD Million) By Region

Table 94: Global Isoniazid Injection Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global Isoniazid Injection Market Volume (K) By Region

Table 111: Global Isoniazid Injection Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

FAQs

1. What is the current Isoniazid Injection market size?

The Isoniazid Injection market size was estimated at USD 1.1 billion in 2023, reflecting steady demand from tuberculosis treatment programs worldwide. This valuation incorporates both branded and generic injectable formulations across public‑sector procurement and private‑care channels.

2. How is the market expected to grow over the forecast period?

The market is projected to expand at a compound annual growth rate of 5.3 % from 2024 to 2032, reaching roughly USD 1.8 billion by the end of the period. Growth is fueled by rising TB incidence in high‑burden regions and increased injection‑based therapy adoption.

3. What are the primary drivers behind market expansion?

Key drivers include government‑backed TB control initiatives, WHO recommendations favoring injectable prophylaxis for drug‑resistant cases, and expanding hospital networks in emerging economies. Additionally, price‑competitive generic production and improved supply‑chain logistics boost accessibility of Isoniazid Injection.

4. What challenges could hinder market adoption?

Challenges arise from stringent cold‑chain requirements, limited intravenous administration expertise in rural clinics, and competition from oral fixed‑dose combinations. Patent expirations have intensified price pressure, while safety concerns about hepatotoxicity demand robust pharmacovigilance, complicating market penetration.

5. Which regions lead in revenue and volume?

North America and Europe currently dominate revenue due to mature healthcare systems, whereas Asia‑Pacific leads in volume, driven by high TB burden in India and China. Latin America shows modest growth, while the Middle East and Africa are emerging markets with increasing procurement programs.

6. Who are the top companies competing in this market?

Leading players include Sanofi, Pfizer, Mylan (Viatris), Cipla, and Lupin, each offering either proprietary or generic Isoniazid Injection formulations. These firms differentiate through extensive distribution networks, strategic partnerships with public health agencies, and continuous investment in manufacturing capacity.

7. What future opportunities exist for manufacturers?

The future outlook highlights opportunities in combination injectable therapies, pediatric dosing devices, and biosimilar development for emerging markets. Digital adherence monitoring and collaborations with NGOs can unlock new revenue streams while supporting global TB eradication goals.

8. How are technological advancements influencing product development?

Advanced lyophilization techniques and closed‑system vials enhance stability, reducing cold‑chain dependency. Automation in aseptic filling improves batch consistency, while real‑time analytics enable rapid detection of impurities, collectively strengthening product quality and expanding market access.

9. What is the regulatory landscape for Isoniazid Injection globally?

Regulatory oversight varies: the US FDA requires NDAs with stringent sterility data, while the EMA follows a centralized procedure for biologics. In emerging regions, WHO prequalification and national drug authority approvals are critical for market entry and reimbursement.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Isoniazid Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	210.00 million
Revenue forecast in 2033	339.79 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Suicheng Pharmaceutical Co.,Ltd.; Southwest Pharmaceutical Co.,Ltd.; Tianjin Kingyork Pharmaccuticals Co.,Ltd.; Jilin Century Hanke Pharmaceutical Co.,Ltd.; Changchun Dazheng Pharmaceutical Technology Co.,Ltd.; Guangzhou Baiyunshan Pharmaceutical Co.,Ltd.; CSPC Pharmaceutical Group Limited; Langzhi Group Wanrong Pharmaceutical Co.,Ltd.; Henan Kelun Pharmaceutical Co.,Ltd.; Shandong Hualu Pharmaceutical Co.,Ltd.; Jiangsu Pengyao Pharmaceutical Co.,Ltd.; Harbin Pharmaceutical Group Co.,Ltd.; Anhui Chengshi Pharmaceutical Co.,Ltd.; Sandoz; AdvaCare; CMP Pharma; Taj Pharmaceuticals Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options